As of Nov 21, 2024, the Regeneron Pharmaceuticals stock's PE ratio is 17.22. This takes into account the latest EPS of $43.24 and stock price of $744.5. The PE ratio marks a decrease of 32% from its last 4 quarters average of 25.2.
The PE ratio of Regeneron Pharmaceuticals has averaged 34.66 over the last ten years. The current P/E ratio of 17.22 is 50% lower than the historical average. Looking back at the last ten years, REGN's PE ratio peaked in the Mar 2015 quarter at 132.01, when the price was $451.48 and the EPS was $3.42. The lowest point was in the Dec 2021 quarter, when it reached 8.27 with a price of $631.52 and an EPS of $76.4.
Maximum annual increase: 115.36% in 2022
Maximum annual decrease: -51.21% in 2016
Year | PE ratio | Change |
---|---|---|
2023 | 23.71 | 33.13% |
2022 | 17.81 | 115.36% |
2021 | 8.27 | -44.12% |
2020 | 14.8 | -23.59% |
2019 | 19.37 | 17.47% |
2018 | 16.49 | -50.57% |
2017 | 33.36 | -22.29% |
2016 | 42.93 | -51.21% |
2015 | 87.99 | -27.94% |
2014 | 122.1 | 87.64% |
REGN's current PE ratio is lower than its 3, 5 and 10-year averages.
REGN's PE ratio stands lower than its peer stocks JNJ and AMGN, but it is higher than NVS's and BIIB's. Regeneron Pharmaceuticals is currently trading at a lower PE ratio (17.22) than its peers average of 22.2.
Stock name | PE ratio | Market cap |
---|---|---|
NVS Novartis AG | 12.03 | $207.63B |
BIIB Biogen Inc | 14.22 | $23.03B |
REGN Regeneron Pharmaceuticals Inc | 17.22 | $81.81B |
JNJ Johnson & Johnson | 25.79 | $374.39B |
AMGN Amgen Inc | 36.74 | $155.83B |
ALNY Alnylam Pharmaceuticals Inc | N/A | $31.83B |
REGN stock has a price to earnings ratio of 17.22 as of Nov 21, 2024.
The 3-year average price to earnings ratio for REGN stock is 18.49.
The 5-year average price to earnings ratio for REGN stock is 17.64.
Over the last ten years, the quarterly PE ratio reached its highest level at 132.01 in the Mar 2015 quarter.
REGN's price to earnings ratio is currently 50% below its 10-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Nov 21, 2024), Regeneron Pharmaceuticals's share price is $744.5. The company's earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $43.24. Therefore, Regeneron Pharmaceuticals's PE ratio for today is 17.22. PE RATIO(17.22) = STOCK PRICE($744.5) / TTM EPS($43.24)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.